BioDev Services has partnered with Kenya’s Africa Clinical Trial Solutions (ACTS), a contract research organization focused on sub-Saharan Africa.
The goal is to strengthen the companies’ geographic outreach in delivering clinical trials and other research programs.
Through the partnership, BioDev, a provider of clinical research and allied services incorporated in 2019, and ACTS’ clients will get the capability to conduct clinical trials in 15 countries in India and sub-Saharan Africa regions. The Partners will use uniform SOPs and tools for conducting clinical trials.
Both companies will also commit investment to create an ecosystem of uniform LMS, QMS, CTMS and other tools – to offer a seamless experience to their clients who want Clinical trial delivery from India and SSA regions together.
Combined geography – India region (India, Bangladesh, Sri Lanka, Nepal, Bhutan) and SSA region (Kenya, Nigeria, Ethiopia, Rwanda, Uganda, Malawi, Zambia, Tanzania, South Africa and Ghana) represent one of the most diverse patient populations.
The sites in these regions offer an exceptional mix of (a) world-class medical expertise & infrastructure (b) research and treatment-naïve patient population and (c) diverse representative ethnicity for clinical trials. The partnership between BioDev and ACTS shall offer an excellent opportunity to global pharmaceutical companies who are looking to conduct clinical research in the combined geography.
Both companies will also continue to offer their services separately to their clients who don’t need delivery from the combined geography.
While BioDev offers over 100 years of experience in conducting international clinical research and offers its services across the R&D value chain from concept to commercialization of biopharma products, Africa Clinical Trial Solutions brings diversity into the clinical trial industry by engaging with institutions that have the capability of running ethical clinical trials with well qualified and experienced doctors and have access to large treatment-naïve patient populations.